We actively take part in public-private partnerships on a national and international level. These collaborations bring a large number of organisations together to conduct precompetitive research.

Public private partnerships

One example is the Top Institute for Food and Nutrition (TIFN). This institute brings together leading food and ingredient manufacturers, personal care companies, research institutes, universities and medical centres. It channels interdisciplinary innovation research in the areas of optimal human nutrition, food safety and sustainable food production, to increase the competitiveness of the food industry.

One of 4 workpages we’re involved in consists of clarifying, in a human context, how gut microbiota can be an important factor connected to obesity. Knowing that most data available through literature is in animal models, TIFN aims at doing intervention studies in humans to characterize the role of gut microbiota in metabolic disease. It enables collaborations between academic experts and labs from very different fields (Metabolism, immunity, gut biology, clinics) and industrial experts (Nestle, Danone, Kellogs….). Our role is to provide ingredients to modulate the microbiome and to make sure the projects keep an application scope


The French research institute INRA embodies leading expertise in the field of Gut Microbiome analysis. Dr. Stanislav Dusko Ehrlich was the coordinator of the MetaHIT EU project, which has delivered 3 publications in Nature. Our objective is to use the unique pipeline for microbiome analysis that INRA has built up. It is a win-win situation, because we have well-designed clinical trials, well-characterized cohorts and they have a unique technology. Together we are closing scientific gaps. For example, we are exploring how the early gut microbiome may predict immune related disease.

Prof. dr. Daniel Tomé is internationally renowned for his research on proteins and physiology. We are currently answering how early feeding of a high protein diet can impact obesity later in life. We bring the paediatric dimension to the discussion, as well as expertise of microbiota. It is a 3-year project aimed at sharing findings through scientific publications.


The LipiDiDiet project is an example of a large EU consortium in a highly specialised scientific area. The project has two main parts. Firstly, there is research into the value of nutritional support in persons at risk for Alzheimer’s disease. Secondly, the project includes the potential therapeutic and preventive effects of dietary lipids in model systems of Alzheimer’s disease and vascular dementia. The LipiDiDiet project is funded with support from the European Commission under the Seventh Framework Programme.